S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Vanda Pharmaceuticals (VNDA) Competitors

$4.06
-0.06 (-1.46%)
(As of 04/15/2024 ET)

VNDA vs. RIGL, MACK, XOMA, VSTM, RGLS, EBS, VBIV, LXRX, ANAB, and INVA

Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Rigel Pharmaceuticals (RIGL), Merrimack Pharmaceuticals (MACK), XOMA (XOMA), Verastem (VSTM), Regulus Therapeutics (RGLS), Emergent BioSolutions (EBS), VBI Vaccines (VBIV), Lexicon Pharmaceuticals (LXRX), AnaptysBio (ANAB), and Innoviva (INVA). These companies are all part of the "medical" sector.

Vanda Pharmaceuticals vs.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 8.4% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 7.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vanda Pharmaceuticals has a net margin of 1.30% compared to Vanda Pharmaceuticals' net margin of -21.47%. Rigel Pharmaceuticals' return on equity of 0.46% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals-21.47% N/A -21.21%
Vanda Pharmaceuticals 1.30%0.46%0.39%

Vanda Pharmaceuticals has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$116.88M1.73-$25.09M-$0.15-7.67
Vanda Pharmaceuticals$192.64M1.21$2.51M$0.0581.22

Vanda Pharmaceuticals received 84 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 68.64% of users gave Vanda Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Rigel PharmaceuticalsOutperform Votes
450
68.81%
Underperform Votes
204
31.19%
Vanda PharmaceuticalsOutperform Votes
534
68.64%
Underperform Votes
244
31.36%

Rigel Pharmaceuticals presently has a consensus price target of $5.81, indicating a potential upside of 405.43%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Vanda Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Vanda Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Rigel Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 4 mentions for Vanda Pharmaceuticals and 3 mentions for Rigel Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.98 beat Rigel Pharmaceuticals' score of 0.80 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vanda Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Vanda Pharmaceuticals beats Rigel Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VNDA vs. The Competition

MetricVanda PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$233.61M$6.66B$4.83B$7.49B
Dividend YieldN/A3.07%5.53%3.96%
P/E Ratio81.2216.64248.9219.11
Price / Sales1.21335.352,495.3991.23
Price / CashN/A20.1333.2728.20
Price / Book0.435.614.674.26
Net Income$2.51M$132.79M$100.02M$210.92M
7 Day Performance-6.88%-5.11%-4.44%-4.38%
1 Month Performance6.56%-4.45%-2.92%-2.08%
1 Year Performance-37.15%3.09%12.64%6.73%

Vanda Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RIGL
Rigel Pharmaceuticals
1.9717 of 5 stars
$1.25
-0.8%
$5.81
+365.0%
-6.5%$219.23M$116.88M-8.33147High Trading Volume
MACK
Merrimack Pharmaceuticals
0 of 5 stars
$14.73
+0.2%
N/A+14.3%$214.06MN/A-184.13426News Coverage
XOMA
XOMA
3.8548 of 5 stars
$25.61
+1.5%
$74.00
+188.9%
+23.7%$298.10M$4.76M-6.3413Positive News
VSTM
Verastem
2.9349 of 5 stars
$11.74
-1.0%
$28.79
+145.2%
+135.4%$300.00M$2.60M-2.8673Short Interest ↓
RGLS
Regulus Therapeutics
3.123 of 5 stars
$2.70
+1.1%
$7.25
+168.5%
+133.6%$176.74MN/A-1.7030
EBS
Emergent BioSolutions
3.9292 of 5 stars
$2.32
flat
$5.00
+116.0%
-83.3%$121.11M$1.02B-0.161,600Short Interest ↑
Positive News
VBIV
VBI Vaccines
1.878 of 5 stars
$0.66
-28.3%
N/A-81.9%$15.64M$1.08M-0.06190Gap Up
High Trading Volume
LXRX
Lexicon Pharmaceuticals
1.0471 of 5 stars
$2.07
-1.0%
$5.00
+141.5%
-22.4%$509.71M$1.20M-2.59285Analyst Upgrade
ANAB
AnaptysBio
2.5271 of 5 stars
$21.53
+4.2%
$44.71
+107.7%
-1.2%$576.14M$17.16M-3.54117
INVA
Innoviva
4.1877 of 5 stars
$14.72
-0.1%
$22.50
+52.9%
+19.8%$930.75M$310.46M6.75112Short Interest ↓
News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:VNDA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners